Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Viking Thera (VKTX)
Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
1 Under-the-Radar Stock That Could Triple By 2030 Motley Fool - Sat Nov 4, 6:30AM CDT

This small-cap biotech stock is going to compete against some giants.

LLY : 589.25 (+0.19%)
VKTX : 17.24 (-0.69%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders FinancialNewsMedia - Thu Oct 19, 7:45AM CDT

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 2.57 (+8.90%)
RYTM : 37.23 (+1.14%)
VKTX : 17.24 (-0.69%)
GPCR : 60.73 (-1.25%)
NVO : 97.59 (-2.05%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders PR Newswire - Thu Oct 19, 7:45AM CDT

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 2.57 (+8.90%)
RYTM : 37.23 (+1.14%)
VKTX : 17.24 (-0.69%)
GPCR : 60.73 (-1.25%)
NVO : 97.59 (-2.05%)
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023 PR Newswire - Wed Oct 18, 3:05PM CDT

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
Wall Street - shutterstock_156562427
Markets Today: Stocks Slip on Set-Back in Diplomatic Efforts to Contain Israel-Hamas Conflict Barchart - Wed Oct 18, 8:11AM CDT

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.48%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.67%. Stock index futures this morning are moderately lower on this morning’s...

ESZ23 : 4,554.25 (-0.04%)
NQZ23 : 15,840.75 (+0.16%)
NVDA : 455.03 (-2.28%)
MS : 79.41 (-0.95%)
IBKR : 80.09 (+1.55%)
UAL : 40.93 (+3.38%)
AAL : 13.48 (+2.67%)
DAL : 38.94 (+3.54%)
ALK : 35.67 (+0.28%)
SHW : 286.71 (+1.31%)
CFG : 28.76 (-1.03%)
ALB : 118.30 (+4.45%)
Wall Street - shutterstock_2269106477
S&P Futures Plunge as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap Barchart - Wed Oct 18, 4:36AM CDT

December S&P 500 futures (ESZ23) are trending down -0.45% this morning as uncertainties lingered in the Middle East, and investors weighed the possibility of further rate hikes by the Federal Reserve while...

ESZ23 : 4,554.25 (-0.04%)
NVDA : 455.03 (-2.28%)
GS : 341.97 (+0.06%)
NTCT : 20.91 (+1.90%)
BAC : 30.53 (-0.16%)
DLTR : 126.03 (-1.35%)
TSLA : 239.37 (+0.27%)
NFLX : 446.73 (-1.85%)
PG : 146.65 (-0.07%)
ABT : 104.94 (+0.57%)
MS : 79.41 (-0.95%)
ADS.D.DX : 194.440 (-1.41%)
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 PR Newswire - Tue Oct 17, 3:05PM CDT

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 PR Newswire - Tue Oct 10, 3:05PM CDT

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)
Charts, tickers, traders - shutterstock_1014224965 (1)
$VKTX: Consolidation in Viking Therapeutics Provides an Opportunity Elliott Wave Forecast - Mon Oct 2, 1:20PM CDT

Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid...

VKTX : 17.24 (-0.69%)
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu Sep 7, 3:05PM CDT

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

VKTX : 17.24 (-0.69%)

Barchart Exclusives

Here's How High Salesforce Stock Might Climb in 2024 Barchart - Wed Dec 6, 2:55PM CST
Goldman Sachs has the Street-high price target for CRM going into 2024, which is leading the Dow this year with its market-crushing gains. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot